Strictly batch-verified with certified HPLC and MS spectra. Direct factory allocation with tamper-evident containment and complete documentation.
A definitive chemical and pharmacological assessment for pharmaceutical formulation engineers, institutional buyers, and regulatory compliance directors seeking uncompromised local anesthetic raw materials.
Gravocain (structurally classified within the high-affinity quinoline-carboxamide anesthetic series, closely aligned with long-acting dibucaine hydrochloride analogs) exhibits exceptional lipophilicity and prolonged nerve membrane residency. Our synthesis relies on multi-step catalytic condensation starting from high-purity 2-chlorocinchoninic acid precursors.
The continuous-flow amidation route incorporates N,N-diethylethylenediamine under strictly controlled thermochemical parameters, eliminating trace isomeric side products and avoiding polycyclic aromatic degradation pathways common in uncontrolled batch synthesis.
In accordance with ICH Q3A(R2) and EP/USP pharmacopeial monographs, every industrial batch of Gravocain undergoes rigorous profiling for organic impurities, volatile residues, and heavy elemental contaminants. Continuous multi-stage recrystallization from certified pharmaceutical solvents guarantees an ultra-pure crystalline lattice.
Residual solvents are systematically reduced via vacuum drying cycles below 0.05% (500 ppm), vastly surpassing standard Class 2 solvent threshold restrictions. Elemental impurities (Pb, As, Cd, Hg) are verified through Inductively Coupled Plasma Mass Spectrometry (ICP-MS) below 0.1 ppm.
Gravocain functions as a potent voltage-gated sodium channel (Nav) antagonist on sensory nerve axolemma. Exhibiting partition coefficients significantly higher than lidocaine or procaine, Gravocain partitions selectively into myelin sheaths, providing profound sensory anesthesia with lower relative mass requirements.
This pharmacodynamic property makes it an indispensable active ingredient in specialized extended-duration dermal ointments, dental surgical sprays, and spinal surgical preparations requiring reliable latency and controlled duration of sensory blockade.
| Analytical Parameter | Gravocain Manufacturer Specification | Pharmacopeia (EP / USP Reference) | Release Method |
|---|---|---|---|
| Chemical Appearance | White to off-white crystalline microfine powder | White or almost white crystalline powder | Visual & Microscopic Morphology |
| HPLC Chromatographic Purity | ≥ 99.60% (Typical batches: 99.82%) | ≥ 99.00% | Reverse Phase HPLC (UV 254 nm) |
| Melting Range (Point) | 63.5°C to 65.5°C (Free Base) | 63.0°C to 66.0°C | Automated Capillary Melting System |
| Loss on Drying / Water Content | ≤ 0.35% | ≤ 0.50% | Karl Fischer Coulometric Titration |
| Bacterial Endotoxin Limit | < 0.25 EU/mg (Injectable / Sterile Grade) | < 0.50 EU/mg | LAL Kinetic Turbidimetric Method |
| Heavy Metals (Pb, Cd, As, Hg) | < 2 ppm Combined total | < 10 ppm | ICP-MS Method (USP <232>/<233>) |
How our facility in Hebei delivers pricing stability, continuous production capacity, and zero-defect raw material continuity to global B2B procurement networks.
The primary vulnerability in western API synthesis stems from fragmented upstream intermediate supplies. Our facility maintains full backward chemical integration into basic chlorination, quinoline nucleus construction, and alkylation reagents. By producing key raw building blocks in-house, we eliminate intermediate price gouging and third-party delivery bottlenecks.
This end-to-end sovereignty ensures that during global chemical raw material fluctuations or environmental supply shocks, our production lines for Gravocain and related specialty anesthetics operate without disruption.
Traditional multi-thousand-liter batch reactors often suffer from thermal gradients and localized hot spots, leading to side-chain polymerizations and color variability. Our facility has transitioned over 60% of catalytic amidation processes to advanced micro-channel continuous flow reactors.
This technological transition provides precise millisecond thermal equilibrium, tighter stoichiometric dosing, enhanced mass transfer, and drastic reductions in carbon emissions and solvent consumption—aligning our factory with international green chemistry mandates.
Operating within the established industrial cluster of Hebei, China, allows our plant to capitalize on regional chemical synergies, optimized power grids, and direct access to high-throughput container ports (Tianjin/Qingdao). We bypass intermediary brokerages, offering global CDMOs and compounding laboratories direct-from-manufacturer wholesale terms.
Our contracts feature long-term price indexation, shielding corporate procurement budgets against currency and ocean freight volatility.
Modern Contract Development & Manufacturing Organizations (CDMOs), finished drug formulators, and multinational distributors evaluate API suppliers through comprehensive operational and regulatory lenses.
Enterprise procurement requires comprehensive Drug Master File (DMF) packages (Type II API in the US and ASMF in Europe). We provide open-part documentation covering route of synthesis, process validation parameters, analytical validation, and stability under accelerated ICH Q1A conditions.
Our quality management system is fully accessible for remote virtual audits and on-site qualification visits. We maintain electronic batch records (EBR), computerized instrument data integrity compliant with 21 CFR Part 11, and archived retains for every production lot for 5+ years.
Formulation teams require customized physical characteristics. We offer controlled air-jet micronization with laser diffraction particle size distribution (D10, D50, D90) curves tailored for suspension sprays, lipophilic ointments, or immediate-release parenteral dissolving systems.
Multinational pharmaceutical enterprises cannot risk single-point manufacturing failure. We maintain parallel qualified production modules and secondary warehouse inventory caches, enabling instant volume shifting if local maintenance or regulatory maintenance cycles arise.
From hospital operating suites to ambulatory veterinary care and over-the-counter dermatological preparations, explore how Gravocain API enables advanced formulation architectures.
In heavy hyperbaric or isobaric injectable preparations, Gravocain provides prolonged sensory denervation without excessive cardiotoxicity when formulated at precise milligram dosages. Its extended motor-sparing sensory block characteristics make it a viable alternative for prolonged obstetric, orthopedic, and lower abdominal interventions.
In aesthetic medicine, laser dermatology, and severe neuropathic pruritus management, deep stratum corneum penetration is essential. Gravocain’s high logP coefficient allows it to solubilize rapidly in lipid matrices, eutectic mixtures (EMLA variants), and microemulsions, producing sustained desensitization without repeated re-application.
Veterinary protocols demand long-acting pain suppression for surgical laceration closure, wound debridement, and mucosal pain relief in livestock and companion animals. High bioavailability via mucous membranes ensures rapid onset followed by multi-hour therapeutic relief, reducing postoperative animal stress and systemic opioid requirements.
Technological breakthroughs in drug delivery platforms are transforming conventional local anesthetic APIs from short-acting block agents into targeted, multi-day sustained release therapeutics.
The success of multivesicular liposomes (pioneered in commercial bupivacaine formulations) has sparked substantial research into Gravocain liposomal carriers. Due to its unique quinoline backbone and lipophilicity, encapsulated Gravocain demonstrates superior membrane retention, offering non-opioid postsurgical site analgesia lasting up to 72–96 hours from a single infiltration.
Formulation laboratories are utilizing poly(lactic-co-glycolic acid) (PLGA) polymers and thermo-responsive hydrogels loaded with Gravocain. These systems remain injectable liquids at room temperature but transition into stable semi-solid drug depots at 37°C in vivo, releasing API at a zero-order kinetics rate without burst-release toxicity.
Global regulatory initiatives (including FDA guidance on reducing surgical opioid dependency) have forced hospitals to adopt Enhanced Recovery After Surgery (ERAS) protocols. High-potency, long-duration local anesthetics like Gravocain serve as cornerstone raw materials for nerve block cocktails and continuous wound infiltration catheters.
Dissolvable polymer microneedle patches incorporating micronized Gravocain are emerging as needle-free alternatives for pediatric vaccination numbing, cannulation, and targeted peripheral neuropathy therapy. The high unit potency ensures therapeutic desensitization with microscopic transdermal delivery volumes.
Navigating international customs declarations, dangerous goods classifications, and chemical registrations requires specialized compliance infrastructure. Here is how we safeguard every consignment.
Misclassification is the leading cause of international shipment impoundment. Our export compliance department verifies Harmonized Tariff System (HS) classifications (specifically under Chapter 29 heterocyclic nitrogen compounds), providing matching proforma invoices, packing declarations, and certificates of origin (CO) accepted worldwide.
Every shipment is accompanied by a compliant 16-section Safety Data Sheet (SDS) generated according to UN GHS Revision 9 standards in English, Spanish, German, or French. For European Union buyers, our compounds are supported by EU REACH declarations and substance volume tracking guarantees.
API powders are packaged inside pharma-grade double polyethylene liners heat-sealed within tamper-proof aluminum foil barrier pouches, shielded from light, humidity, and atmospheric oxygen, then placed in UN-certified fiber drums. We offer door-to-door DDP air express or ocean freight with real-time temperature tracking.
Key clarifications on synthesis purity, analytical validation, storage stability, minimum orders, and international shipping protocols.
Gravocain Free Base is non-ionized, displaying elevated lipophilicity and excellent solubility in lipid carriers, organic excipients, and oily bases, making it the choice for topical creams, transdermal ointments, and mucosal gels. Gravocain Hydrochloride (HCl) is the water-soluble salt form, readily dissolving in aqueous physiological buffers and saline, making it ideal for parenteral injections, subarachnoid solutions, and hydrophilic liquid dental sprays. Both forms are produced in our facility with identical purity standards (≥99.5%).
Every production batch is tested against secondary reference standards. We provide a full Certificate of Analysis (COA) containing exact batch assay percentages, reverse-phase high-performance liquid chromatography (RP-HPLC) chromatograms showing peak integration, mass spectrometry (MS) confirming molecular mass, proton nuclear magnetic resonance (1H-NMR) spectra for structural confirmation, and Karl Fischer titration data. Third-party testing verification (e.g., SGS, Eurofins) is available upon request.
To assist formulation R&D and pilot-stage testing, our initial evaluation sample MOQ starts as low as 100 grams to 1 kilogram, complete with analytical documentation. For commercial procurement, we support standard drum orders ranging from 25 kg fiber drums up to multi-metric-ton scheduled annual deliveries with locked volume pricing contracts.
When stored in its original, unopened amber vacuum-sealed packaging in a cool, dry area protected from light at controlled room temperature (15°C–25°C, or 2°C–8°C for prolonged raw powder storage), Gravocain demonstrates exceptional chemical stability. Accelerated and real-time ICH stability studies support a documented retest period of 36 months from the date of manufacture.
Our facilities comply with strict national Chinese Green Production Standards and ISO 14001 / ISO 45001 certifications. We utilize closed-loop solvent recovery systems recovering >92% of organic process solvents, on-site catalytic oxidation for VOC exhaust purification, and advanced biochemical wastewater treatment stations, ensuring total production sustainability and zero regulatory shutdown risks.
Browse additional high-purity chemical and peptide reference materials manufactured under strict quality oversight with worldwide express dispatch.
Connect directly with our chemical export engineering team. Inquiries are processed with full analytical documentation, HPLC chromatographic traces, and tiered B2B pricing within 24 business hours.
